Biotech Firms Raised $405 Million in Dual M&A Deals
Lisata Therapeutics and Aethlon Medical secured fresh capital alongside mergers to fund pipeline development.
Updated on Sept. 21, 2026 in Healthcare
Live Poll
Do you trust that biotech reverse mergers generally prioritize the interests of retail shareholders?
Lisata Therapeutics acquired Marea Therapeutics and Aethlon Medical combined with North Immunology in two separate all-stock transactions. Both firms simultaneously secured private placements to finance their respective clinical pipelines.
Why it matters
These deals provide the capital and strategic scope necessary to advance specialized therapeutic candidates in hypertriglyceridemia and atopic dermatitis. They reflect a broader push by mid-cap biotech firms to secure public platforms for high-stakes clinical development.
The companies raised a total of $405 million via private placements, consisting of $225 million for Lisata and $180 million for Aethlon. These capital injections support assets including the MAR001/005 antibody and the NOR-101 bispecific candidate.
The players
Lisata Therapeutics
A biotechnology company focused on developing therapies for solid tumors and cardioendocrine diseases.
Aethlon Medical
A medical technology company specializing in therapeutic blood filtration and, following this merger, immunology research.
Marea Therapeutics
A research-focused firm developing monoclonal antibodies for metabolic conditions.
North Immunology
An immunology-focused developer known for the NOR-101 bispecific antibody candidate.
The details
Lisata acquired Marea Therapeutics through a stock-for-stock transaction, pivoting its focus toward cardioendocrine disease. Aethlon Medical opted for an all-stock merger with North Immunology, creating a combined entity that will trade under the ticker NRTX. Both organizations are leveraging these structural changes to support long-term R&D, specifically for candidates like the NOR-101 bispecific antibody, which demonstrated a 42-day half-life in pre-clinical primate studies.
Timeline
August 2026 marked the collapse of Lisata's previously planned merger with Kuva Labs.
September 21, 2026, served as the announcement date for the new merger and placement deals.
Clinical data readouts for North Immunology's NOR-101 are expected through 2028.
Market Landscape
These transactions follow the high-profile 2026 collapse of Lisata's planned merger with Kuva Labs. The current consolidation signals a sector-wide trend where firms are pairing stock-for-stock acquisitions with immediate private capital to stabilize development pipelines.
Operators should note that the dual-track strategy of combining mergers with private placements is a recurring model for firms aiming to maintain liquidity while pursuing long-term clinical readouts. Business leaders should monitor the ticker NRTX as a bellwether for the execution success of this specific merger-and-funding structure.
The takeaway
The move demonstrates that even after failed M&A attempts, public biotech firms remain aggressive in using equity-based structural pivots to secure development capital. Management teams should track the upcoming data readouts for NOR-101 as a signal of whether this new corporate structure translates into competitive clinical outcomes.
What happens next
Investors and industry observers should watch for multiple data readouts for North Immunology's NOR-101 program occurring periodically through 2028.
Further reading
For more on the consolidation trends shaping the industry, see the latest updates in Healthcare.
Source note: This article includes information reported by BioXconomy.
Live Poll
Do you trust that biotech reverse mergers generally prioritize the interests of retail shareholders?
